Spark Therapeutics Inc (NASDAQ:ONCE) has been assigned a consensus rating of “Buy” from the twenty research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $86.50.

Several equities research analysts have recently commented on ONCE shares. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a report on Friday, August 25th. William Blair started coverage on shares of Spark Therapeutics in a research report on Wednesday, June 28th. They issued an “outperform” rating on the stock. ValuEngine raised shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Chardan Capital raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $60.00 to $100.00 in a research report on Tuesday, August 8th. Finally, BidaskClub raised shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 5,669 shares of Spark Therapeutics stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $65.00, for a total transaction of $368,485.00. Following the completion of the sale, the chief executive officer now directly owns 235,669 shares in the company, valued at approximately $15,318,485. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Daniel Faga sold 1,500 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the sale, the insider now owns 1,500 shares of the company’s stock, valued at $127,500. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,338,864 shares of company stock valued at $109,438,991. Company insiders own 7.30% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of ONCE. Ameritas Investment Partners Inc. lifted its stake in shares of Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Spark Therapeutics in the 2nd quarter valued at $143,000. BNP Paribas Arbitrage SA lifted its stake in shares of Spark Therapeutics by 530.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,449 shares during the period. Pacad Investment Ltd. lifted its stake in shares of Spark Therapeutics by 75.0% in the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC acquired a new position in shares of Spark Therapeutics in the 1st quarter valued at $227,000. Hedge funds and other institutional investors own 77.84% of the company’s stock.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down 0.08% during midday trading on Wednesday, reaching $89.16. 466,144 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $82.71 and its 200 day moving average price is $82.71. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $91.00. The company’s market cap is $2.79 billion.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing the consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 5,013.37% and a negative return on equity of 115.22%. The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. During the same quarter in the prior year, the firm posted ($1.04) EPS. The company’s revenue for the quarter was up 14.7% compared to the same quarter last year. Equities analysts anticipate that Spark Therapeutics will post ($7.69) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/spark-therapeutics-inc-once-receives-86-50-average-target-price-from-analysts/1599450.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.